Metagenomi Therapeutics Gross Profit 2022-2026 | MGX

Metagenomi Therapeutics gross profit from 2022 to 2026. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Metagenomi Therapeutics Annual Gross Profit
(Millions of US $)
2025 $25
2024 $52
2023 $45
2022 $17
2021 $0
Metagenomi Therapeutics Quarterly Gross Profit
(Millions of US $)
2026-03-31 $1
2025-12-31 $4
2025-09-30 $9
2025-06-30 $9
2025-03-31 $4
2024-12-31 $10
2024-09-30 $12
2024-06-30 $20
2024-03-31 $11
2023-12-31 $12
2023-09-30 $12
2023-06-30 $11
2023-03-31 $9
2022-12-31
2021-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.052B $0.025B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $35.437B 10.97
BridgeBio Pharma (BBIO) United States $14.460B 0.00
Dr Reddy's Laboratories (RDY) India $11.109B 17.29
Aspen Pharmacare (APNHY) South Africa $3.708B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.918B 22.33
Bausch Health Cos (BHC) Canada $2.086B 1.50
Taysha Gene Therapies (TSHA) United States $1.290B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.924B 7.28
Personalis (PSNL) United States $0.630B 0.00
Assembly Biosciences (ASMB) United States $0.451B 0.00
Sol-Gel Technologies (SLGL) Israel $0.210B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00